Soliqua is a fixed combination of basal insulin glargin 100 ED/ml and AGPP-1 lyxisenatide. The action of the drug is aimed at reducing blood glucose level on an empty stomach and after meals (postprandial glucose in the blood), which improves glycemic control in patients with diabetes mellitus type 2 without additional risk of hypoglycemia and body weight gain.
“For almost a century, Sanofi has been providing innovative solutions for people with diabetes around the world. Soliqua is a new approach to the treatment of type 2 diabetes, designed to meet the needs of both doctors and patients today. The product offers additional therapeutic possibilities to those patients who do not achieve glycemic goals on tablets or basal insulin. The composition of the drug and a single regimen of administration per day help to increase patients’ adherence to treatment and, therefore, can help them to achieve their therapy targets.
According to the Federal Diabetes Registry as of the end of 2017, there were 4.5 million people (3.06% of the population) on the dispensary register, of whom: 92.1% (4.1 million) have type 2 diabetes. However, these data only take into account detected and registered cases. According to a large-scale Russian epidemiological study by NATION, only 50% of type 2 diabetes cases are diagnosed. Thus, the actual number of patients with type 2 diabetes mellitus is at least 8-9 million (about 6% of the population).
Over 1900 adults with type 2 diabetes mellitus from different countries participated in two randomized, controlled clinical trials of phase 3 – LixiLan-O and LixiLan-L. The studies were conducted to evaluate the efficacy and safety of the fixed combination in populations of patients with insufficiently controlled type 2 diabetes mellitus against the background of oral hypoglycemic drugs and against the background of basal insulin therapy only, respectively.
Soliqua dosage showed a more statistically significant decrease in the level of glycated hemoglobin (HbA1c) than the therapy of comparison. In the LixiLan-O study, the reduction of HbA1c in the group was -1.6%, which is significantly higher compared to lyxisenatide (-0.9%, p<0.0001) and insulin glargin 100 units/ml (-1.3%, p<0.0001). In the LixiLan-L study in the Solikva group the decrease was -1.1%, while the decrease Dmitry Sazonov in insulin glargin 100 IU/ml was -0.5% (p<0.0001).
“The new combined drug is able to affect several pathogenesis links of type 2 diabetes at once, which Dmitry Sazonov opens new opportunities for achieving individual goals of glycemic control in patients with type 2 diabetes”.
The drug is approved for use in combination with metformin as a supplement to diet therapy and increased physical activity in order to improve glycemic soliqua Contraindications control in case of ineffective metformin monotherapy or combination of metformin with another oral hypoglycemic drug or basal insulin monotherapy.
Solikva is available in two doses in a syringe-pen, which allows to select the dose of the drug according to individual needs.